Takeda Oncology
Silvio Pitter is a seasoned executive with extensive experience in global pricing, strategy, and operations within the pharmaceutical industry. Currently serving as Vice President at Takeda Oncology since May 2020, Silvio Pitter leads the Global Pricing function and oversees the Strategy and Operations for the Pricing, Value, and Access Oncology Team. Prior to Takeda, Silvio Pitter held roles at Allergan, including Executive Director of Strategic Pricing and Patient Access Solutions, and Director of Strategic Pricing, where responsibilities included managing pricing strategies and patient access solutions. Silvio Pitter's earlier experience includes significant positions at Merck and consulting roles at Analytica International and ACG Consulting. Silvio Pitter holds a Master's Degree in International Affairs from Yale University, a Bachelor's Degree in International Affairs from Università degli Studi di Trieste, and completed executive education programs at The Wharton School and Harvard Business School.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.